This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market

Market Insights on Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment covering sales outlook, demand forecast & up-to-date key trends

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market by Drug Class (Glycopeptides, Oxazolidinones, Lipopeptides, Antiseptics, Lipoglycopeptides, Glycylcycline, Streptogramins, Naturals/Herbals, Tetracycline, Lincomycin and Others) & Region for 2022-2030

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Snapshot

[328 Pages Report] The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market was valued at US$ 3.8 Bn in 2021 and is expected to reach US$ 5.5 Bn by 2030, finds Future Market Insights (FMI) in a recent market survey.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Outlook:

Data Points

Market Insights

Market Value 2022

USD 3.9 Bn

Market Value 2030

USD 5.5 Bn

CAGR 2022-2030

4.3%

Key Players

The key players are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC,  Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herbal Intervention, LLC, 3M ESPE Dental Products, Patterson Dental Supply Inc., The Kroger Company, Crown Laboratories, Inc., Atlantic Biologicals Corp., Bio-Germ Protection LLC and Apollo Health and Beauty Care

Share of Top 5 Countries           

65.9%

The methicillin-resistant staphylococcus aureus (MRSA) treatment market is anticipated to witness robust growth due to the growing incidence rate of MRSA infections, increasing number of pipeline products, and growing product approval & launches for the MRSA infection treatment.

One of the significant type of MRSA infection is surgical infections. This risk of infections is associated with several surgical conditions which demand surgical procedures. Rising number of surgical conditions from chronic diseases such as diabetes, chronic respiratory and renal diseases are expected to increase the demand of post-operative MRSA anti-infective therapies.

Methicillin-resistant staphylococcus aureus (MRSA) treatment market holds nearly 18.1% market value share of the US$ 21 Bn skin disease treatment market in 2021. In addition, leading industry players are focusing on development and launch of next generation antibiotics to treat MRSA infections. This accelerated availability of antibiotics in the market is expected to boost the MRSA treatment market.

Driven by this, sales of methicillin-resistant staphylococcus aureus (MRSA) treatment are expected to rise at a 4.3% CAGR through 2030.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

4.25%

H1, 2022 Projected

4.34%

H1, 2022 Outlook

4.24%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 10 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 1 ↓

FMI presents a comparative analysis about the market growth rates and development prospects in the global methicillin resistant Staphylococcus aureus (MRSA) treatment market. In response to the impact of macro and industrial factors, the market is influenced by an increase in patient base and economic disparities in regional medical setups. Source control and the initiation of active antimicrobial therapy are two major advancements in this sector.

The market for methicillin-resistant Staphylococcus aureus (MRSA) therapy is expected to fall by just 01 Basis Point Share (BPS) in H1-2022, according to FMI. The disruption created by the COVID-19 pandemic, as well as the lack of clear protocols for MRSA treatment in numerous countries, are key factors in the decline of BPS. Moreover, a decline of 10 BPS will be observed in the market within the periods of H1-2022 outlook over H1-2022 projected.

On the other hand, there are certain advantages for the industry, such as combination therapy with Vancomycin and Daptomycin. Physicians employ heterogeneous practice patterns with vancomycin or daptomycin monotherapy for MRSA, with combination antibiotic therapy reserved for patients at higher risk of treatment failure.

2015-2021 Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Demand Outlook Compared to 2022-2030 Forecast

Sales of methicillin-resistant staphylococcus aureus (MRSA) treatment grew at a CAGR of 4.1% between 2015 and 2021.

The primary factors contributing to the development of the methicillin-resistant staphylococcus aureus (MRSA) treatment market are increase in the worldwide occurrence of MRSA infections, a rise in public and private funding for R&D of new anti-MRSA drugs and their enhanced screening.

For instance, as per the CDC, around 2% of the overall population carries MRSA. Moreover, the growing practice of prescribing inappropriate and unnecessary antibiotics leading to the increase in MRSA infections is expected to boost the growth of the global market.

In addition, companies are focusing on product releases and research for the detection of MRSA, which is boosting the global MRSA treatment market.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Download Report Brochure

For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market.

Considering this, FMI expects the global methicillin-resistant staphylococcus aureus (MRSA) treatment market to grow at a CAGR of 4.3% through 2030.

Which Factors Are Restraining Demand for Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment?

Poor access to MRSA treatment and misdiagnoses of MRSA infections are the primary factors limiting the growth of the MSRA treatment market.

S. aureus and MRSA produce considerable economic challenges for healthcare professionals owing to the effect they have on quality of care, patient safety, and overall healthcare expenses. High cost related with MRSA infections treatment is anticipated to hinder the treatment adoption rate specifically in emerging regions.

In addition, incorrect diagnoses of MRSA may result into inappropriate delivery and management of patient care, which, in turn, results into severe primary and secondary complications, including death. All such factors may hinder the market growth in the near future.

Country-Wise Insights

What Makes the U.S. a Large Market for Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment?

The U.S. is estimated to account for around 93.2% of the North America methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.  

U.S. is anticipated to lead the global MRSA treatment market over the forecast period. This market share is majorly owing to the funding by U.S. based companies in the research and development of assessment tools for MRSA infection. In addition, the increase in government support for treatment of MRSA lung infection in patients with cystic fibrosis has boosted the market.

For instance, Cystic Fibrosis Foundation, in 2018, at North American Cystic Fibrosis Conference declared that it will spend a minimum of USD 100 million for the next five years to support enhanced diagnosis, detection, prevention, and treatment of infections associated to cystic fibrosis.

Why is U.K. Considered a Lucrative Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market?

U.K. is estimated to account for 14.7% of the Europe methicillin-resistant staphylococcus aureus (MRSA) treatment market in 2022.

U.K. is the one of the prominent country in the European market owing to research grants by the private & public companies in the European countries to boost the research and development of anti-MRSA antibiotics.

In addition, the government of the UK is undertaking serious steps to avoid the incidence of SSI (surgical site infections) in the nation. Thus, the increasing efforts and preventive measures undertaken by the government for surgical site infections control are leading to the growth of the market in U.K.

What are the Factors Fueling the Demand for Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment in China?

The methicillin-resistant staphylococcus aureus (MRSA) treatment market in China is estimated to be worth US$ 156.6 Mn in 2022 in the global market.

China is expected to observe considerable growth during the forecast period owing to a huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.

For instance, in 2017, Basilea Pharmaceutica Ltd. entered into a licensed agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for expansion of Basilea's antibiotic Zevtera, broad spectrum anti-bacterial, which can address MRSA in China, Hong Kong, and Macao

How will the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market Expand across India?

Demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in India is expected to rise at around 5.4% CAGR over the forecast period.

India is expected to witness considerable growth owing to larger patient population and the uncontrolled utilization of antibiotics in India. Resistance to antibiotics is continuously growing due to incomplete prescribed course of antibiotics that allows some bacteria to persist, grow a resistance to the antibiotic.

Moreover, misuse of antibiotics in non-regulated and developing nations is also anticipated to drive the cases of MRSA infections in the coming years. This is leading to increasing demand for the MRSA infection treatment.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Category-Wise Insights

Demand for Glycopeptides to continue gaining Traction

By drug class, glycopeptides is anticipated to hold the maximum share of 61.2% in 2022, expanding at rate of nearly 4.1% during the forecast period, due to growing focus of market players on manufacturing of advanced drugs in this class. Vancomycin and teicoplanin are some of the present glycopeptide drugs in the market.

Moreover, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.

Why Skin and Soft Tissue Infections (SSTIs) will hold the most of the market share?

By indication, skin and soft tissue infections (SSTIs) will lead the market and is projected to account for 40.9% of the total market revenue share in 2022.

The growing incidence of MRSA (methicillin-resistant staphylococcus aureus) infections has led to the need for novel therapies to fight the serious skin and soft tissue infections. Moreover, new product launches will drive the growth of the skin and soft tissue infections (SSTIs) segment over the forecast period.

Why Intravenous route is the most preferred route of administration?

In terms of route of administration, intravenous segment in projected to account for 57.2% of the total market share in 2022. 

The intravenous route of administration is the most preferred route as it is the first line of therapy and the fastest route of drug delivery. This delivers the drug rapidly and gives the patient rapid relieve from the disease. This enhances the drug action and gives the patient first line of treatment.

Why Healthcare Acquired MRSA will hold the most of the market share?

By types of MRSA, healthcare acquired MRSA will lead the market and is projected to account for 51.2% of the total market revenue share in 2022.

Hospital-acquired MRSA hospitalizations are those with a secondary or principal MRSA detection that is not present on admission; this indicates that the MRSA condition occurred during the hospitalization. The hospital acquired MSRA cases is increasing due to the rising number of surgical procedures and unhygienic conditions.

Why Hospital pharmacies projected maximum growth in the Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market?

By distribution channel, hospital pharmacies segment is anticipated to hold the maximum share of 62.6% in 2022, expanding at rapid rate of 3.9% CAGR during the forecast period.

The number of hospitals are growing, particularly in the developed nations, which is anticipated to surge the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment in hospitals. Moreover, presence of well-developed infrastructure and availability of advanced equipment supports the development of the segment.

Also, the increasing patient admission in hospitals is increasing the use of these drugs in hospitals, thus driving the sales in hospital pharmacies.

Competitive Landscape

Companies operating in the Methicillin-Resistant Staphylococcus Aureus (MRSA) treatment market are moderately competitive by nature, with a presence of several players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerates the manufacturer’s strategy to capitalize on the market share and capture the significant share of market. Some of the recent instances include:

  • In July 2021, Melinta Therapeutics announced the commercial launch of KIMYRSA, a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.
  • In January 2020, Wockhardt announced regulatory approval to two novel antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The new drug will target superbug like Methicillin-resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance.
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Scope Of The Report

Attribute

Details

Forecast Period

2015-2021

Historical Data Available for

2022-2030

Market Analysis

USD Million for Value

Key Countries Covered

US, Canada, Brazil, Mexico, Argentina, Germany, U.K., France, Italy, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa

Key Segments Covered

Drug Class, Indication, Route of Administration, Types of MSRA, Distribution Channel and Region

Key Companies Profiled

  • Pfizer, Inc.  
  • Allergan Plc.
  • Johnsons & Johnson
  • Colgate-Palmolive Company
  • The Procter & Gamble
  • Merck & Co., Inc.
  • Baxter Healthcare Corporation
  • Fresenius Kabi LLC
  • Sandoz Inc.
  • Teva Pharmaceutical Industries ltd.
  • Mylan N. V.
  • Dr.Reddy's Laboratories Inc.,
  • Cumberland Pharmaceuticals Inc.
  • Durata Therapeutics Inc.
  • Melinta Therapeutics, Inc.
  • Debiopharm International S.A.
  • Cardinal Health
  • Amazon Inc.
  • Herbal Intervention, LLC
  • 3M ESPE Dental Products
  • Patterson Dental Supply Inc.
  • The Kroger Company
  • Crown Laboratories, Inc.
  • Atlantic Biologicals Corp.
  • Bio-Germ Protection LLC
  • Apollo Health and Beauty Care

Report Coverage

Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market By Category

By Drug Class :

  • Glycopeptides
    • Vancomycin
  • Oxazolidinones
    • Linezolid
  • Lipopeptides
    • Daptomycin
  • Antiseptics
    • Chlorhexidine
    • Cetylpyridinium Chloride
    • Hydrogen Peroxide
    • Phenols
  • Lipoglycopeptides
    • Dalbavancin
    • Telavancin
    • Oritavancin
  • Glycylcycline
    • Tigecycline
  • Streptogramins
    • Quinupristin
    • Dalfopristin
  • Naturals/Herbals
  • Tetracycline
    • Doxycycline
    • Minocycline
  • Lincomycin
    • Clindamycin
  • Others

By Indication :

  • Skin and Soft Tissue Infections (SSTIs)
  • Pneumonia
  • Bloodstream Infections
  • Surgical and Medical Infections
  • Others

By Route of Administration :

  • Intravenous
  • Oral
  • Topical
  • Nasal
  • Cutaneous
  • Intramuscular

By Type of MSRA :

  • Healthcare Acquired MRSA
  • Community Acquired MRSA
  • Hospital Acquired MRSA

By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region :

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global methicillin-resistant staphylococcus aureus (MRSA) treatment market is worth US$ 3.8 Bn in 2021 and is set to expand 1.4X over the forecast years.

The sales of methicillin-resistant staphylococcus aureus (MRSA) treatment in the market have grown at a CAGR of nearly 4.1% between 2015 and 2021.

The methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to reach US$ 5.5 Bn by the end of 2030 with sales revenue expected to register CAGR of 4.3% over the forecast period.

North America currently holds the largest market share in the methicillin-resistant staphylococcus aureus (MRSA) treatment with an estimation of nearly 48.5% in 2022 of the global market share. U.S. continues to be the leading contributor with a market value over US$ 1.7 Bn in 2022.

Demand of methicillin-resistant staphylococcus aureus (MRSA) treatment market is expected to register growth in Europe at rate of 4.4% CAGR during the forecast period.

The methicillin-resistant staphylococcus aureus (MRSA) treatment in China is likely to observe growth with an impressive CAGR of 5.1% during the forecast period. The key factors fueling the development of the market include huge patient pool and growing number of expansion strategies by key players to grow their presence in the country.

Development of alternative oral & topical dosage forms, extension of antibiotic class to newer therapeutics, rise of specialized companies in antibiotics developments and commercialization and national healthcare authority’s active engagement to combat MRSA are key trends driving sales of methicillin-resistant staphylococcus aureus (MRSA) treatment market across the globe.

Japan’s methicillin-resistant staphylococcus aureus (MRSA) treatment market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 5.6% CAGR during the forecast period. South Korea market expected to exhibit healthy growth of 7.0% CAGR during the forecast period.

U.S., Germany, France, U.K. and Italy are the top 5 countries driving the demand for methicillin-resistant staphylococcus aureus (MRSA) treatment market.

Leading companies of methicillin-resistant staphylococcus aureus (MRSA) treatment are Pfizer, Inc., Allergan Plc., Johnsons & Johnson, Colgate-Palmolive Company, The Procter & Gamble, Merck & Co., Inc., Baxter Healthcare Corporation, Fresenius Kabi LLC, Sandoz Inc., Teva Pharmaceutical Industries ltd., Mylan N. V., Dr.Reddy's Laboratories Inc., Cumberland Pharmaceuticals Inc., Durata Therapeutics Inc., Melinta Therapeutics, Inc., Debiopharm International S.A., Cardinal Health, Amazon Inc., Herb

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Background

    4.1. COVID19 Crisis Analysis

        4.1.1. Current COVID19 Statistics and Probable Future Impact

        4.1.2. Current GDP Projection and Probable Impact

        4.1.3. Current Economic Projection as compared to 2008 Economic analysis

        4.1.4. COVID19 and Impact Analysis

            4.1.4.1. Revenue By Drug Class

            4.1.4.2. Revenue By Route of Administration

            4.1.4.3. Revenue By Country

        4.1.5. 2020 Market Scenario

        4.1.6. Quarter by Quarter Forecast

        4.1.7. Projected recovery Quarter

        4.1.8. Recovery Scenario – Short term, Midterm and Long Term Impact

    4.2. Macro-Economic Factors

        4.2.1. Global GDP Growth Outlook

        4.2.2. Global Healthcare Outlook

    4.3. Forecast Factors - Relevance & Impact

        4.3.1. Historical Growth of Top Players

        4.3.2. New Product Approval and Launch

        4.3.3. Adoption of MRSA Treatment

        4.3.4. Cost of MRSA Treatment

        4.3.5. Increasing Epidemic of MRSA Infections

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints

        4.4.3. Opportunities

5. Market Context

    5.1. Product USPs/ Features

    5.2. Epidemiological Forecast for MRSA (2014–2024)

        5.2.1. Hospitalized Incident Cases of MRSA

        5.2.2. Sex-Specific Hospitalized Incident Cases of MRSA

        5.2.3. Age-Specific Hospitalized Incidence of MRSA

        5.2.4. Age-Standardized Hospitalized Incidence Rate of MRSA

    5.3. Pipeline Assessment

        5.3.1. Pipeline Overview

        5.3.2. Pipeline Breakdown by Region/Country

        5.3.3. Pipeline Breakdown by Molecule Type and Target

        5.3.4. Drug Review Designations

        5.3.5. Products in Clinical Development

    5.4. New Product Approvals

    5.5. Clinical Trial Assessment

        5.5.1. Clinical Trials Overview

        5.5.2. Top Sponsors of Clinical Trials in MRSA

        5.5.3. Trial Breakdown by Region

        5.5.4. Therapy Area Perspective

        5.5.5. Enrolment Analytics

    5.6. Product Adoption / Route of Administration Analysis

    5.7. Regulatory Scenario

6. Global MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast, 2022-2030

    6.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2030

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Opportunity Analysis, 2022-2030

7. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Drug Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015-2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022-2030

        7.3.1. Glycopeptides

                7.3.1.1. Vancomycin

        7.3.2. Lipopeptides

                7.3.2.1. Daptomycin

        7.3.3. Oxazolidinones

                7.3.3.1. Linezolid

        7.3.4. Glycylcycline

                7.3.4.1. Tigecycline

        7.3.5. Streptogramins

                7.3.5.1. Quinupristin

                7.3.5.2. Dalfopristin

        7.3.6. Lincomycin

                7.3.6.1. Clindamycin

        7.3.7. Tetracycline

                7.3.7.1. Doxycycline

                7.3.7.2. Minocycline

        7.3.8. Lipoglycopeptides

                7.3.8.1. Dalbavancin

                7.3.8.12. Telavancin

                7.3.8.3. Oritavancin

        7.3.9. Antiseptics 

                7.3.9.1. Chlorhexidine

                7.3.9.2. Cetylpyridinium Chloride

                7.3.9.3. Hydrogen Peroxide

                7.3.9.4. Phenols

        7.3.10. Naturals/Herbals

        7.3.11. Others

    7.4. Market Attractiveness Analysis By Drug Class

8. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2030

        8.3.1. Skin and Soft Tissue Infections (SSTIs)

        8.3.2. Pneumonia

        8.3.3. Bloodstream Infections

        8.3.4. Surgical and Medical Infections

        8.3.5. Others

    8.4. Market Attractiveness Analysis By Indication

9. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2030

        9.3.1. Intravenous

        9.3.2. Oral

        9.3.3. Topical

        9.3.4. Nasal

        9.3.5. Cutaneous

        9.3.6. Intramuscular

    9.4. Market Attractiveness Analysis By Route of Administration

10. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Types of MRSA

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Types of MRSA, 2022-2030

        10.3.1. Healthcare Acquired MRSA

        10.3.2. Community Acquired MRSA

        10.3.3. Hospital Acquired MRSA

    10.4. Market Attractiveness Analysis By Types of MRSA

11. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, By Distribution Channels

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channels, 2015-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channels, 2022-2030

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Drug Stores

        11.3.4. Online Pharmacies

    11.4. Market Attractiveness Analysis By Distribution Channels

12. Global MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030, by Region

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2030

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia Pacific

        12.3.6. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Drug Class

        13.3.3. By Indication

        13.3.4. By Route of Administration

        13.3.5. By Types of MRSA

        13.3.6. By Distribution Channels

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. Latin America MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        14.3.1. By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Drug Class

        14.3.3. By Indication

        14.3.4. By Route of Administration

        14.3.5. By Types of MRSA

        14.3.6. By Distribution Channels

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. Europe MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Drug Class

        15.3.3. By Indication

        15.3.4. By Route of Administration

        15.3.5. By Types of MRSA

        15.3.6. By Distribution Channels

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. South Asia and Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. ASEAN

            16.3.1.3. Australia

            16.3.1.4. New Zealand

        16.3.2. By Drug Class

        16.3.3. By Indication

        16.3.4. By Route of Administration

        16.3.5. By Types of MRSA

        16.3.6. By Distribution Channels

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. East Asia MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Drug Class

        17.3.3. By Indication

        17.3.4. By Route of Administration

        17.3.5. By Types of MRSA

        17.3.6. By Distribution Channels

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Oceania MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Drug Class

        18.3.3. By Indication

        18.3.4. By Route of Administration

        18.3.5. By Types of MRSA

        18.3.6. By Distribution Channels

    18.4. Market Attractiveness Analysis

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

19. Middle East and Africa MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015-2021

    19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2030

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. Rest of Middle East and Africa

        19.3.2. By Drug Class

        19.3.3. By Indication

        19.3.4. By Route of Administration

        19.3.5. By Types of MRSA

        19.3.6. By Distribution Channels

    19.4. Market Attractiveness Analysis

    19.5. Key Market Participants - Intensity Mapping

    19.6. Drivers and Restraints - Impact Analysis

20. Emerging Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    20.1. Introduction

        20.1.1. Market Value Proportion Analysis, By Key Countries

        20.1.2. Global Vs. Country Growth Comparison

    20.2. China MRSA Treatment Market Analysis

        20.2.1. By Drug Class

        20.2.2. By Indication

        20.2.3. By Route of Administration

        20.2.4. By Types of MRSA

        20.2.5. By Distribution Channels

    20.3. India MRSA Treatment Market Analysis

        20.3.1. By Drug Class

        20.3.2. By Indication

        20.3.3. By Route of Administration

        20.3.4. By Types of MRSA

        20.3.5. By Distribution Channels

    20.4. Brazil MRSA Treatment Market Analysis

        20.4.1. By Drug Class

        20.4.2. By Indication

        20.4.3. By Route of Administration

        20.4.4. By Types of MRSA

        20.4.5. By Distribution Channels

21. Key Countries MRSA Treatment Market Analysis 2015-2021 and Forecast 2022-2030

    21.1. U.S. MRSA Treatment Market Analysis

        21.1.1. By Drug Class

        21.1.2. By Indication

        21.1.3. By Route of Administration

        21.1.4. By Types of MRSA

        21.1.5. By Distribution Channels

    21.2. Canada MRSA Treatment Market Analysis

        21.2.1. By Drug Class

        21.2.2. By Indication

        21.2.3. By Route of Administration

        21.2.4. By Types of MRSA

        21.2.5. By Distribution Channels

    21.3. Mexico MRSA Treatment Market Analysis

        21.3.1. By Drug Class

        21.3.2. By Indication

        21.3.3. By Route of Administration

        21.3.4. By Types of MRSA

        21.3.5. By Distribution Channels

    21.4. U.K. MRSA Treatment Market Analysis

        21.4.1. By Drug Class

        21.4.2. By Indication

        21.4.3. By Route of Administration

        21.4.4. By Types of MRSA

        21.4.5. By Distribution Channels

    21.5. Germany MRSA Treatment Market Analysis

        21.5.1. By Drug Class

        21.5.2. By Indication

        21.5.3. By Route of Administration

        21.5.4. By Types of MRSA

        21.5.5. By Distribution Channels

    21.6. France MRSA Treatment Market Analysis

        21.6.1. By Drug Class

        21.6.2. By Indication

        21.6.3. By Route of Administration

        21.6.4. By Types of MRSA

        21.6.5. By Distribution Channels

    21.7. Italy MRSA Treatment Market Analysis

        21.7.1. By Drug Class

        21.7.2. By Indication

        21.7.3. By Route of Administration

        21.7.4. By Types of MRSA

        21.7.5. By Distribution Channels

    21.8. Spain MRSA Treatment Market Analysis

        21.8.1. By Drug Class

        21.8.2. By Indication

        21.8.3. By Route of Administration

        21.8.4. By Types of MRSA

        21.8.5. By Distribution Channels

    21.9. BENELUX MRSA Treatment Market Analysis

        21.9.1. By Drug Class

        21.9.2. By Indication

        21.9.3. By Route of Administration

        21.9.4. By Types of MRSA

        21.9.5. By Distribution Channels

    21.10. Russia MRSA Treatment Market Analysis

        21.10.1. By Drug Class

        21.10.2. By Indication

        21.10.3. By Route of Administration

        21.10.4. By Types of MRSA

        21.10.5. By Distribution Channels

    21.11. Japan MRSA Treatment Market Analysis

        21.11.1. By Drug Class

        21.11.2. By Indication

        21.11.3. By Route of Administration

        21.11.4. By Types of MRSA

        21.11.5. By Distribution Channels

    21.12. South Korea MRSA Treatment Market Analysis

        21.12.1. By Drug Class

        21.12.2. By Indication

        21.12.3. By Route of Administration

        21.12.4. By Types of MRSA

        21.12.5. By Distribution Channels

    21.13. ASEAN MRSA Treatment Market Analysis

        21.13.1. By Drug Class

        21.13.2. By Indication

        21.13.3. By Route of Administration

        21.13.4. By Types of MRSA

        21.13.5. By Distribution Channels

    21.14. Australia MRSA Treatment Market Analysis

        21.14.1. By Drug Class

        21.14.2. By Indication

        21.14.3. By Route of Administration

        21.14.4. By Types of MRSA

        21.14.5. By Distribution Channels

    21.15. New Zealand MRSA Treatment Market Analysis

        21.15.1. By Drug Class

        21.15.2. By Indication

        21.15.3. By Route of Administration

        21.15.4. By Types of MRSA

        21.15.5. By Distribution Channels

    21.16. GCC Countries MRSA Treatment Market Analysis

        21.16.1. By Drug Class

        21.16.2. By Indication

        21.16.3. By Route of Administration

        21.16.4. By Types of MRSA

        21.16.5. By Distribution Channels

    21.17. Turkey MRSA Treatment Market Analysis

        21.17.1. By Drug Class

        21.17.2. By Indication

        21.17.3. By Route of Administration

        21.17.4. By Types of MRSA

        21.17.5. By Distribution Channels

    21.18. South Africa MRSA Treatment Market Analysis

        21.18.1. By Drug Class

        21.18.2. By Indication

        21.18.3. By Route of Administration

        21.18.4. By Types of MRSA

        21.18.5. By Distribution Channels

22. Market Structure Analysis

    22.1. Market Analysis by Tier of Companies

    22.2. Market Share Analysis of Top Players

    22.3. Market Presence Analysis

        22.3.1. Regional Footprint by Players

        22.3.2. Product Foot print by Players

        22.3.3. Channel Foot Print by Players

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Benchmarking

    23.3. Competition Deep Dive (Tentative List)

        23.3.1. Pfizer, Inc.

            23.3.1.1. Overview

            23.3.1.2. Product Portfolio

            23.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.1.4. Sales Footprint

            23.3.1.5. Strategy Overview

                23.3.1.5.1. Marketing Strategy

                23.3.1.5.2. Product Strategy

                23.3.1.5.3. Channel Strategy

        23.3.2. Allergan Plc.

            23.3.2.1. Overview

            23.3.2.2. Product Portfolio

            23.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.2.4. Sales Footprint

            23.3.2.5. Strategy Overview

                23.3.2.5.1. Marketing Strategy

                23.3.2.5.2. Product Strategy

                23.3.2.5.3. Channel Strategy

        23.3.3. Johnsons & Johnson

            23.3.3.1. Overview

            23.3.3.2. Product Portfolio

            23.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.3.4. Sales Footprint

            23.3.3.5. Strategy Overview

                23.3.3.5.1. Marketing Strategy

                23.3.3.5.2. Product Strategy

                23.3.3.5.3. Channel Strategy

        23.3.4. Colgate-Palmolive Company

            23.3.4.1. Overview

            23.3.4.2. Product Portfolio

            23.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.4.4. Sales Footprint

            23.3.4.5. Strategy Overview

                23.3.4.5.1. Marketing Strategy

                23.3.4.5.2. Product Strategy

                23.3.4.5.3. Channel Strategy

        23.3.5. The Procter & Gamble

            23.3.5.1. Overview

            23.3.5.2. Product Portfolio

            23.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.5.4. Sales Footprint

            23.3.5.5. Strategy Overview

                23.3.5.5.1. Marketing Strategy

                23.3.5.5.2. Product Strategy

                23.3.5.5.3. Channel Strategy

        23.3.6. Merck & Co., Inc.

            23.3.6.1. Overview

            23.3.6.2. Product Portfolio

            23.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.6.4. Sales Footprint

            23.3.6.5. Strategy Overview

                23.3.6.5.1. Marketing Strategy

                23.3.6.5.2. Product Strategy

                23.3.6.5.3. Channel Strategy

        23.3.7. Baxter Healthcare Corporation

            23.3.7.1. Overview

            23.3.7.2. Product Portfolio

            23.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.7.4. Sales Footprint

            23.3.7.5. Strategy Overview

                23.3.7.5.1. Marketing Strategy

                23.3.7.5.2. Product Strategy

                23.3.7.5.3. Channel Strategy

        23.3.8. Fresenius Kabi LLC

            23.3.8.1. Overview

            23.3.8.2. Product Portfolio

            23.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.8.4. Sales Footprint

            23.3.8.5. Strategy Overview

                23.3.8.5.1. Marketing Strategy

                23.3.8.5.2. Product Strategy

                23.3.8.5.3. Channel Strategy

        23.3.9. Sandoz Inc.

            23.3.9.1. Overview

            23.3.9.2. Product Portfolio

            23.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.9.4. Sales Footprint

            23.3.9.5. Strategy Overview

                23.3.9.5.1. Marketing Strategy

                23.3.9.5.2. Product Strategy

                23.3.9.5.3. Channel Strategy

        23.3.10. Teva Pharmaceutical Industries ltd.

            23.3.10.1. Overview

            23.3.10.2. Product Portfolio

            23.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.10.4. Sales Footprint

            23.3.10.5. Strategy Overview

                23.3.10.5.1. Marketing Strategy

                23.3.10.5.2. Product Strategy

                23.3.10.5.3. Channel Strategy

        23.3.11. Mylan N. V.

            23.3.11.1. Overview

            23.3.11.2. Product Portfolio

            23.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.11.4. Sales Footprint

            23.3.11.5. Strategy Overview

                23.3.11.5.1. Marketing Strategy

                23.3.11.5.2. Product Strategy

                23.3.11.5.3. Channel Strategy

        23.3.12. Dr.Reddy's Laboratories Inc.,

            23.3.12.1. Overview

            23.3.12.2. Product Portfolio

            23.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.12.4. Sales Footprint

            23.3.12.5. Strategy Overview

                23.3.12.5.1. Marketing Strategy

                23.3.12.5.2. Product Strategy

                23.3.12.5.3. Channel Strategy

        23.3.13. Cumberland Pharmaceuticals Inc.

            23.3.13.1. Overview

            23.3.13.2. Product Portfolio

            23.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.13.4. Sales Footprint

            23.3.13.5. Strategy Overview

                23.3.13.5.1. Marketing Strategy

                23.3.13.5.2. Product Strategy

                23.3.13.5.3. Channel Strategy

        23.3.14. Durata Therapeutics Inc.

            23.3.14.1. Overview

            23.3.14.2. Product Portfolio

            23.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.14.4. Sales Footprint

            23.3.14.5. Strategy Overview

                23.3.14.5.1. Marketing Strategy

                23.3.14.5.2. Product Strategy

                23.3.14.5.3. Channel Strategy

        23.3.15. Melinta Therapeutics, Inc.

            23.3.15.1. Overview

            23.3.15.2. Product Portfolio

            23.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.15.4. Sales Footprint

            23.3.15.5. Strategy Overview

                23.3.15.5.1. Marketing Strategy

                23.3.15.5.2. Product Strategy

                23.3.15.5.3. Channel Strategy

        23.3.16. Debiopharm International S.A.

            23.3.16.1. Overview

            23.3.16.2. Product Portfolio

            23.3.16.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.16.4. Sales Footprint

            23.3.16.5. Strategy Overview

                23.3.16.5.1. Marketing Strategy

                23.3.16.5.2. Product Strategy

                23.3.16.5.3. Channel Strategy

        23.3.17. Cardinal Health

            23.3.17.1. Overview

            23.3.17.2. Product Portfolio

            23.3.17.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.17.4. Sales Footprint

            23.3.17.5. Strategy Overview

                23.3.17.5.1. Marketing Strategy

                23.3.17.5.2. Product Strategy

                23.3.17.5.3. Channel Strategy

        23.3.18. Amazon Inc.

            23.3.18.1. Overview

            23.3.18.2. Product Portfolio

            23.3.18.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.18.4. Sales Footprint

            23.3.18.5. Strategy Overview

                23.3.18.5.1. Marketing Strategy

                23.3.18.5.2. Product Strategy

                23.3.18.5.3. Channel Strategy

        23.3.19. Herbal Intervention, LLC

            23.3.19.1. Overview

            23.3.19.2. Product Portfolio

            23.3.19.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.19.4. Sales Footprint

            23.3.19.5. Strategy Overview

                23.3.19.5.1. Marketing Strategy

                23.3.19.5.2. Product Strategy

                23.3.19.5.3. Channel Strategy

        23.3.20. 3M ESPE Dental Products

            23.3.20.1. Overview

            23.3.20.2. Product Portfolio

            23.3.20.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.20.4. Sales Footprint

            23.3.20.5. Strategy Overview

                23.3.20.5.1. Marketing Strategy

                23.3.20.5.2. Product Strategy

                23.3.20.5.3. Channel Strategy

        23.3.21. Patterson Dental Supply Inc.

            23.3.21.1. Overview

            23.3.21.2. Product Portfolio

            23.3.21.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.21.4. Sales Footprint

            23.3.21.5. Strategy Overview

                23.3.21.5.1. Marketing Strategy

                23.3.21.5.2. Product Strategy

                23.3.21.5.3. Channel Strategy

        23.3.22. The Kroger Company

            23.3.22.1. Overview

            23.3.22.2. Product Portfolio

            23.3.22.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.22.4. Sales Footprint

            23.3.22.5. Strategy Overview

                23.3.22.5.1. Marketing Strategy

                23.3.22.5.2. Product Strategy

                23.3.22.5.3. Channel Strategy

        23.3.23. Crown Laboratories, Inc.

            23.3.23.1. Overview

            23.3.23.2. Product Portfolio

            23.3.23.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.23.4. Sales Footprint

            23.3.23.5. Strategy Overview

                23.3.23.5.1. Marketing Strategy

                23.3.23.5.2. Product Strategy

                23.3.23.5.3. Channel Strategy

        23.3.24. Atlantic Biologicals Corp.

            23.3.24.1. Overview

            23.3.24.2. Product Portfolio

            23.3.24.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.24.4. Sales Footprint

            23.3.24.5. Strategy Overview

                23.3.24.5.1. Marketing Strategy

                23.3.24.5.2. Product Strategy

                23.3.24.5.3. Channel Strategy

        23.3.25. Bio-Germ Protection LLC

            23.3.25.1. Overview

            23.3.25.2. Product Portfolio

            23.3.25.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.25.4. Sales Footprint

            23.3.25.5. Strategy Overview

                23.3.25.5.1. Marketing Strategy

                23.3.25.5.2. Product Strategy

                23.3.25.5.3. Channel Strategy

        23.3.26. Apollo Health and Beauty Care

            23.3.26.1. Overview

            23.3.26.2. Product Portfolio

            23.3.26.3. Profitability by Market Segments (Product/Channel/Region)

            23.3.26.4. Sales Footprint

            23.3.26.5. Strategy Overview

                23.3.26.5.1. Marketing Strategy

                23.3.26.5.2. Product Strategy

                23.3.26.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 02: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 03: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 04: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 05: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 06: Global MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Region

Table 07: North America MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 08: North America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 09: North America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 10: North America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 11: North America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 12: North America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 13: Latin America MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 14: Latin America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 15: Latin America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 16: Latin America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 17: Latin America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 18: Latin America MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 19: Europe MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 20: Europe MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 21: Europe MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 22: Europe MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 23: Europe MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 24: Europe MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 25: South Asia MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 26: South Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 27: South Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 28: South Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 29: South Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 30: South Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 31: East Asia MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 32: East Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 33: East Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 34: East Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 35: East Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 36: East Asia MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 37: Oceania MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 38: Oceania MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 39: Oceania MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 40: Oceania MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 41: Oceania MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 42: Oceania MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 43: MEA MRSA Treatment Market Value (US$ Mn) Analysis 2015-2021 and Forecast 2022-2030, By Country

Table 44: MEA MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 45: MEA MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 46: MEA MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 47: MEA MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 48: MEA MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 49: China MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 50: China MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 51: China MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 52: China MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 53: China MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 54: India MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 55: India MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 56: India MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 57: India MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 58: India MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Table 59: Brazil MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Drug Class

Table 60: Brazil MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Indication

Table 61: Brazil MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Route of Administration

Table 62: Brazil MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Types of MRSA

Table 63: Brazil MRSA Treatment Market Value (US$ Mn) Analysis and Opportunity Assessment 2015–2030, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 01: Global MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 02: Global MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 03: Global MRSA Treatment Market Absolute $ Opportunity, 2022-2030

Figure 04: Global MRSA Treatment Market Share Analysis (%), By Drug Class, 2022-2030

Figure 05: Global MRSA Treatment Market Y-o-Y Analysis (%), By Drug Class, 2022-2030

Figure 06: Global MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 07: Global MRSA Treatment Market Share Analysis (%), By Indication, 2022-2030

Figure 08: Global MRSA Treatment Market Y-o-Y Analysis (%), By Indication, 2022-2030

Figure 09: Global MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 10: Global MRSA Treatment Market Share Analysis (%), By Route of Administration, 2022-2030

Figure 11: Global MRSA Treatment Market Y-o-Y Analysis (%), By Route of Administration, 2022-2030

Figure 12: Global MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 13: Global MRSA Treatment Market Share Analysis (%), By Types of MRSA, 2022-2030

Figure 14: Global MRSA Treatment Market Y-o-Y Analysis (%), By Types of MRSA, 2022-2030

Figure 15: Global MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 16: Global MRSA Treatment Market Share Analysis (%), By Distribution Channel, 2022-2030

Figure 17: Global MRSA Treatment Market Y-o-Y Analysis (%), By Distribution Channel, 2022-2030

Figure 18: Global MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 19: Global MRSA Treatment Market Share Analysis (%), By Region, 2022-2030

Figure 20: Global MRSA Treatment Market Y-o-Y Analysis (%), By Region, 2022-2030

Figure 21: Global MRSA Treatment Market Attractiveness Analysis by Region, 2022-2030

Figure 22: North America MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 23: North America MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 24: North America MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 25: North America MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 26: North America MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Figure 27: North America MRSA Treatment Market Value Share, By Country, 2022 (E)

Figure 28: North America MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 29: North America MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 30: North America MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 31: North America MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 32: North America MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 33: North America MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 34: North America MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 35: North America MRSA Treatment Market Attractiveness Analysis by Country, 2022-2030

Figure 36: Latin America MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 37: Latin America MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 38: Latin America MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 39: Latin America MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 40: Latin America MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Figure 41: Latin America MRSA Treatment Market Value Share, By Country, 2022 (E)

Figure 42: Latin America MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 43: Latin America MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 44: Latin America MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 45: Latin America MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 46: Latin America MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 47: Latin America MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 48: Latin America MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 49: Latin America MRSA Treatment Market Attractiveness Analysis by Country, 2022-2030

Figure 50: Europe MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 51: Europe MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 52: Europe MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 53: Europe MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 54: Europe MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Figure 55: Europe MRSA Treatment Market Value Share, By Country, 2022 (E)

Figure 56: Europe MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 57: Europe MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 58: Europe MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 59: Europe MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 60: Europe MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 61: Europe MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 62: Europe MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 63: Europe MRSA Treatment Market Attractiveness Analysis by Country, 2022-2030

Figure 64: South Asia MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 65: South Asia MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 66: South Asia MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 67: South Asia MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 68: South Asia MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Figure 69: South Asia MRSA Treatment Market Value Share, By Country, 2022 (E)

Figure 70: South Asia MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 71: South Asia MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 72: South Asia MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 73: South Asia MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 74: South Asia MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 75: South Asia MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 76: South Asia MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 77: South Asia MRSA Treatment Market Attractiveness Analysis by Country, 2022-2030

Figure 78: East Asia MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 79: East Asia MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 80: East Asia MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 81: East Asia MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 82: East Asia MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Figure 83: East Asia MRSA Treatment Market Value Share, By Country, 2022 (E)

Figure 84: East Asia MRSA Treatment Market Value Analysis (US$ Mn), 2015-2021

Figure 85: East Asia MRSA Treatment Market Value Forecast (US$ Mn), 2022-2030

Figure 86: East Asia MRSA Treatment Market Attractiveness Analysis by Drug Class, 2022-2030

Figure 87: East Asia MRSA Treatment Market Attractiveness Analysis by Route of Administration, 2022-2030

Figure 88: East Asia MRSA Treatment Market Attractiveness Analysis by Indication, 2022-2030

Figure 89: East Asia MRSA Treatment Market Attractiveness Analysis by Types of MRSA, 2022-2030

Figure 90: East Asia MRSA Treatment Market Attractiveness Analysis by Distribution Channel, 2022-2030

Figure 91: East Asia MRSA Treatment Market Attractiveness Analysis by Country, 2022-2030

Figure 92: Oceania MRSA Treatment Market Value Share, By Drug Class, 2022 (E)

Figure 93: Oceania MRSA Treatment Market Value Share, By Route of Administration, 2022 (E)

Figure 94: Oceania MRSA Treatment Market Value Share, By Indications, 2022 (E)

Figure 95: Oceania MRSA Treatment Market Value Share, By Types of MRSA, 2022 (E)

Figure 96: Oceania MRSA Treatment Market Value Share, By Distribution Channel, 2022 (E)

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Infection Prevention Market

Published : September 2021

Healthcare

Staphylococcus Aureus Testing Market

Published : October 2017

Google translate

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Market